SciELO - Scientific Electronic Library Online

 
vol.42 issue1A view of training neurologists in Chile: we should be doing our bestNeurological Consultations in Intensive Care author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista chilena de neuro-psiquiatría

On-line version ISSN 0717-9227

Abstract

MIRANDA, Marcelo  and  AZALDEGUI, Octavio. Neuroprotective therapy in Parkinson’s Disease. Rev. chil. neuro-psiquiatr. [online]. 2004, vol.42, n.1, pp.49-52. ISSN 0717-9227.  http://dx.doi.org/10.4067/S0717-92272004000100007.

With the current limitations on treating Parkinson’s disease, neuroprotection should be looked at as a possible way of slowing the varying processes involved in the onset of the disease. A review was made of the work of NINDS experts, who evaluated 59 drugs resulting from their Medline and Pub Med search. Twelve drugs, those considered the most promising, were included in the final analysis. We look at such substances as caffeine, coenzyme q10, estrogens, minocycline, nicotine, rasagiline-selegiline, and ropinirole-pramipexole. These agents acted dissimilarly, but favorably, on some of the disease’s processes or on its underlying pathogenesis, although the mechanisms involved and the duration of the beneficial effects were not clear. The challenge is to overcome the difficulties that make the results of the few current studies uncertain, using new methods, such as transgenic models, to maintain hope for effective future treatments.

Keywords : Parkinson’s Disease; neuroprotective terapy.

        · text in Spanish

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License